Makes blood collection tubes whose chemistry and color codes are built into hospital laboratory robots worldwide.
At a glance
- Depends onUpstream position: supplies 4 industries, depends on 0
- ScaleMarket cap is in the top 5% of all stocks globally
Makes blood collection tubes whose chemistry and color codes are built into hospital laboratory robots worldwide.
What this company is and how it runs — written from structure, not news.
Becton, Dickinson and Company makes blood collection tubes — called BD Vacutainers — where each tube contains a proprietary chemical formula that stabilizes specific substances in blood, and the tube's exact color and barrel diameter tell hospital laboratory robots how to handle that specimen. Because the automation software running those robots is written to BD's precise dimensions, even a millimeter of deviation jams the specimen line, so every hospital laboratory running automated diagnostics is physically locked to BD's manufacturing specifications. Switching to a different tube supplier means reprogramming the robots, revalidating every affected diagnostic protocol under FDA oversight, and amending the hospital's laboratory information systems — a sequence that cannot be compressed below 18 to 24 months per device configuration, which means hospitals remain tied to BD for the entire working life of each instrument. The one thing that could unwind all of this is if a major laboratory automation vendor rewrote its specimen-routing software to accept an open tube standard rather than BD's proprietary dimensions, because that single change would dissolve the switching cost that currently makes the chemistry formulations so difficult to challenge.
How does this company make money?
BD sells disposable devices — tubes, syringes, reagents — one unit at a time, primarily through medical distributors Cardinal Health and McKesson. Large hospital groups buy through Group Purchasing Organizations, which offer rebates when a hospital commits enough of its purchasing to BD products. BD also places flow cytometry instruments like the FACSymphony into laboratories and then earns ongoing revenue selling the reagent panels those instruments require to run tests.
What makes this company hard to replace?
Hospital laboratory information systems are written with BD Vacutainer color codes built in. Changing suppliers means updating that software and getting regulatory sign-off on every diagnostic protocol the system touches. For prefillable syringes, the FDA requires 18 to 24 months of testing to prove a replacement syringe mechanism is equally safe. For pharmaceutical companies, the problem is even more direct: their FDA drug approval files name BD's specific syringe configuration, so switching requires formally amending those filings and waiting for the agency to accept the change.
What limits this company?
Before BD can change anything on a production line — adding a new tube size, retooling a mold — the FDA requires 90 days of biological safety testing to confirm the new setup is still sterile. That mandatory waiting period means BD cannot quickly add capacity when demand spikes or when something disrupts supply. Growth must be planned far in advance.
What does this company depend on?
BD relies on Japanese suppliers for the cyclic olefin copolymer resin used to make prefillable syringe barrels. It needs FDA 510(k) clearance for each device it sells, and it must maintain ISO 13485 certification at its manufacturing sites to keep those clearances valid. Its proprietary additive chemistries are the core of the Vacutainer tube business, and access to Group Purchasing Organization contracts is what gets those tubes into hospital supply chains at scale.
Who depends on this company?
Hospital laboratories depend on BD Vacutainer tube color codes to run their automated specimen lines — without those tubes, the robots cannot route samples and testing slows to manual speeds. Pharmaceutical companies that fill biologics into BD prefillable syringes cannot simply switch to a different syringe because their drug approval filings name BD's specific configuration, and changing that requires FDA permission. Clinical laboratories running BD FACSymphony flow cytometers are locked to BD's own reagent panels, because those instruments are built to work with BD's chemistry and nothing else.
How does this company scale?
Once the FDA has validated the settings for an injection molding line at one facility, BD can copy those settings to additional facilities without starting the approval process from scratch — that part of growth is relatively straightforward. What does not scale easily is the regulatory work itself. Every new device submission to the FDA requires experienced staff who understand that specific product category and know how individual FDA reviewers think. That expertise cannot be automated or replaced by hiring generalists.
What external forces can significantly affect this company?
When the Centers for Medicare & Medicaid Services cuts the reimbursement rates hospitals receive for procedures, hospitals buy fewer consumables — which reduces demand for BD's tubes and syringes. In Europe, the EU Medical Device Regulation now requires more clinical evidence for products that were already on the market, adding cost and time to keeping existing products available. At the same time, aging populations in many countries are driving higher demand for injectable biologics, which needs the kind of specialized delivery devices BD makes.
Where is this company structurally vulnerable?
If a major laboratory robot maker — one whose machines already sit in hospitals everywhere — rewrote its software to accept any tube geometry instead of only BD's, the lock-in would disappear overnight. Hospitals would no longer face years of revalidation work to switch suppliers, and the protection BD's chemical formulas currently enjoy would collapse with it.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three depreciation observations align at elevated readings: depreciation is large relative to operating cash flow (industry-benchmarked), depreciation is a large share of EBITDA, and accumulated depreciation is a large share of gross properties. Together they describe a depreciation-heavy profile across three denominators.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph